A citation-based method for searching scientific literature

Zobair M Younossi. J Hepatol 2019
Times Cited: 831







List of co-cited articles
457 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Zobair M Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer. Hepatology 2016
23

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
18

Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
David E Kleiner, Elizabeth M Brunt, Mark Van Natta, Cynthia Behling, Melissa J Contos, Oscar W Cummings, Linda D Ferrell, Yao-Chang Liu, Michael S Torbenson, Aynur Unalp-Arida,[...]. Hepatology 2005
15

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
Zobair Younossi, Quentin M Anstee, Milena Marietti, Timothy Hardy, Linda Henry, Mohammed Eslam, Jacob George, Elisabetta Bugianesi. Nat Rev Gastroenterol Hepatol 2018
15


NAFLD: a multisystem disease.
Christopher D Byrne, Giovanni Targher. J Hepatol 2015
12

Mechanisms of NAFLD development and therapeutic strategies.
Scott L Friedman, Brent A Neuschwander-Tetri, Mary Rinella, Arun J Sanyal. Nat Med 2018
12

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam, Philip N Newsome, Shiv K Sarin, Quentin M Anstee, Giovanni Targher, Manuel Romero-Gomez, Shira Zelber-Sagi, Vincent Wai-Sun Wong, Jean-François Dufour, Jörn M Schattenberg,[...]. J Hepatol 2020
10

Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Norbert Stefan, Hans-Ulrich Häring, Kenneth Cusi. Lancet Diabetes Endocrinol 2019
381
10

Nonalcoholic Fatty Liver Disease 2020: The State of the Disease.
Thomas G Cotter, Mary Rinella. Gastroenterology 2020
354
9

Non-alcoholic fatty liver disease.
Elizabeth E Powell, Vincent Wai-Sun Wong, Mary Rinella. Lancet 2021
307
8

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Chris Estes, Quentin M Anstee, Maria Teresa Arias-Loste, Heike Bantel, Stefano Bellentani, Joan Caballeria, Massimo Colombo, Antonio Craxi, Javier Crespo, Christopher P Day,[...]. J Hepatol 2018
672
8

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.
Daniel Q Huang, Hashem B El-Serag, Rohit Loomba. Nat Rev Gastroenterol Hepatol 2021
410
8

Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba. Gastroenterology 2019
567
7

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).
Elena Buzzetti, Massimo Pinzani, Emmanuel A Tsochatzis. Metabolism 2016
7

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
975
7

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Philip N Newsome, Kristine Buchholtz, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun J Sanyal, Anne-Sophie Sejling, Stephen A Harrison. N Engl J Med 2021
393
7

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
Stuart McPherson, Tim Hardy, Elsbeth Henderson, Alastair D Burt, Christopher P Day, Quentin M Anstee. J Hepatol 2015
627
7

Mechanisms and disease consequences of nonalcoholic fatty liver disease.
Rohit Loomba, Scott L Friedman, Gerald I Shulman. Cell 2021
268
7

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.
Giovanni Targher, Christopher D Byrne, Amedeo Lonardo, Giacomo Zoppini, Corrado Barbui. J Hepatol 2016
681
6

Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps.
Amedeo Lonardo, Fabio Nascimbeni, Stefano Ballestri, DeLisa Fairweather, Sanda Win, Tin A Than, Manal F Abdelmalek, Ayako Suzuki. Hepatology 2019
325
6

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.
Siddharth Singh, Alina M Allen, Zhen Wang, Larry J Prokop, Mohammad H Murad, Rohit Loomba. Clin Gastroenterol Hepatol 2015
859
6

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
Parambir S Dulai, Siddharth Singh, Janki Patel, Meera Soni, Larry J Prokop, Zobair Younossi, Giada Sebastiani, Mattias Ekstedt, Hannes Hagstrom, Patrik Nasr,[...]. Hepatology 2017
916
6

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
Paul Angulo, David E Kleiner, Sanne Dam-Larsen, Leon A Adams, Einar S Bjornsson, Phunchai Charatcharoenwitthaya, Peter R Mills, Jill C Keach, Heather D Lafferty, Alisha Stahler,[...]. Gastroenterology 2015
6

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.
Chris Estes, Homie Razavi, Rohit Loomba, Zobair Younossi, Arun J Sanyal. Hepatology 2018
924
6

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Eduardo Vilar-Gomez, Yadina Martinez-Perez, Luis Calzadilla-Bertot, Ana Torres-Gonzalez, Bienvenido Gra-Oramas, Licet Gonzalez-Fabian, Scott L Friedman, Moises Diago, Manuel Romero-Gomez. Gastroenterology 2015
6

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.
Quentin M Anstee, Giovanni Targher, Christopher P Day. Nat Rev Gastroenterol Hepatol 2013
6

Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease.
Reenam S Khan, Fernando Bril, Kenneth Cusi, Philip N Newsome. Hepatology 2019
194
6


Nonalcoholic Steatohepatitis: A Review.
Adam C Sheka, Oyedele Adeyi, Julie Thompson, Bilal Hameed, Peter A Crawford, Sayeed Ikramuddin. JAMA 2020
399
6

The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.
Giorgio Bedogni, Stefano Bellentani, Lucia Miglioli, Flora Masutti, Marilena Passalacqua, Anna Castiglione, Claudio Tiribelli. BMC Gastroenterol 2006
5

Complications, morbidity and mortality of nonalcoholic fatty liver disease.
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, Anna Alisi, Christopher D Byrne, Giovanni Targher. Metabolism 2020
178
5

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
Mattias Ekstedt, Hannes Hagström, Patrik Nasr, Mats Fredrikson, Per Stål, Stergios Kechagias, Rolf Hultcrantz. Hepatology 2015
5

Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.
Jie Li, Biyao Zou, Yee Hui Yeo, Yuemin Feng, Xiaoyu Xie, Dong Hyun Lee, Hideki Fujii, Yuankai Wu, Leslie Y Kam, Fanpu Ji,[...]. Lancet Gastroenterol Hepatol 2019
361
5

From NASH to HCC: current concepts and future challenges.
Quentin M Anstee, Helen L Reeves, Elena Kotsiliti, Olivier Govaere, Mathias Heikenwalder. Nat Rev Gastroenterol Hepatol 2019
545
5

Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments.
Hironori Kitade, Guanliang Chen, Yinhua Ni, Tsuguhito Ota. Nutrients 2017
233
5


Treatment of NAFLD with diet, physical activity and exercise.
Manuel Romero-Gómez, Shira Zelber-Sagi, Michael Trenell. J Hepatol 2017
552
5

The role of the gut microbiota in NAFLD.
Christopher Leung, Leni Rivera, John B Furness, Peter W Angus. Nat Rev Gastroenterol Hepatol 2016
475
5

Advancing the global public health agenda for NAFLD: a consensus statement.
Jeffrey V Lazarus, Henry E Mark, Quentin M Anstee, Juan Pablo Arab, Rachel L Batterham, Laurent Castera, Helena Cortez-Pinto, Javier Crespo, Kenneth Cusi, M Ashworth Dirac,[...]. Nat Rev Gastroenterol Hepatol 2022
105
5



Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.
Kerry L Donnelly, Coleman I Smith, Sarah J Schwarzenberg, Jose Jessurun, Mark D Boldt, Elizabeth J Parks. J Clin Invest 2005
5

Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease.
Jeong-Hoon Lee, Donghee Kim, Hwa Jung Kim, Chang-Hoon Lee, Jong In Yang, Won Kim, Yoon Jun Kim, Jung-Hwan Yoon, Sang-Heon Cho, Myung-Whun Sung,[...]. Dig Liver Dis 2010
592
4


Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance.
Ruth C R Meex, Matthew J Watt. Nat Rev Endocrinol 2017
298
4

Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Rod S Taylor, Rebecca J Taylor, Sue Bayliss, Hannes Hagström, Patrik Nasr, Jorn M Schattenberg, Masatoshi Ishigami, Hidenori Toyoda, Vincent Wai-Sun Wong, Noam Peleg,[...]. Gastroenterology 2020
340
4

The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.
Paul Angulo, Jason M Hui, Giulio Marchesini, Ellisabetta Bugianesi, Jacob George, Geoffrey C Farrell, Felicity Enders, Sushma Saksena, Alastair D Burt, John P Bida,[...]. Hepatology 2007
4

Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
David E Kleiner, Elizabeth M Brunt, Laura A Wilson, Cynthia Behling, Cynthia Guy, Melissa Contos, Oscar Cummings, Matthew Yeh, Ryan Gill, Naga Chalasani,[...]. JAMA Netw Open 2019
147
4

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Ulf Hammar, Per Stål, Rolf Hultcrantz, Stergios Kechagias. J Hepatol 2017
485
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.